WALTHAM, Mass.– Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced today the appointment of Leslie Orne as Chief Executive Officer (CEO) effective July 1. Ms. Orne, who is currently the President and Chief Commercial Officer at Trinity, succeeds David Fitzhenry, who has held various leadership roles at Trinity for 26 years. Mr. Fitzhenry will remain active with the Company as a strategic advisor and member of the Board of Directors.
Ms. Orne, who is also a member of Trinity’s Board of Directors, has over 20 years of leadership experience consulting in the life sciences industry. She has overseen the delivery of integrated consulting, insights and analytics services to Trinity’s 300+ clients since 2001. Her support for billions of dollars in strategic transactions and the launches of dozens of products gives Leslie a unique vantage point on the industry. Her evidence-forward approach to strategic questions empowers customers to make smart, informed and timely decisions. She has played an integral role in Trinity’s acquisitions over the last few years, shepherding the integration of BluePrint Research Group, CBPartners and D Cube Analytics into the Trinity fold. Ms. Orne has also spearheaded Trinity’s strategic partnerships with Bain & Company and Havas Health & You.
“Leslie will usher in an even more innovative era for the Company, demonstrating to life science clients the true power of using insights and analytics to revolutionize the commercial model,” said Matt Jennings, Chairman of Trinity Life Sciences’ Board of Directors. “In addition, we would like to extend a heartfelt thank you to David Fitzhenry for his enterprising and magnanimous leadership. He has built amazing teams, a strong culture and a truly differentiated offering that has set up Trinity for great success for many years to come.”
“Trinity has consistently outpaced the market in terms of growth, and we have never been better positioned than we are today to have a real influence on getting the right products to the right patients at the right time,” said David Fitzhenry, current CEO of Trinity Life Sciences. “Leslie’s laser-focused growth mindset will be essential during the next chapter of Trinity’s expansion.”
“Trinity is rapidly advancing the commercialization approach of the life science industry. Their deep industry expertise, powerful tools and focus on evidence-based insights drive commercialization forward for some of the most innovative therapies and devices in the industry,” said Anne Whitaker, Member, Trinity Life Sciences Board of Directors. “Leslie has been a critical advisor to hundreds of customers across thousands of projects, spanning an array of therapeutic areas and business models. She has seamlessly integrated solutions to meet the distinct needs of emerging biotech firms and established pharmaceutical companies and every type of organization in between. In her new role as CEO, Leslie will no doubt guide Trinity to new heights.”
“Trinity’s vision, mission and values are extremely important to me, and none of that will change. Someday we or someone we love will be patients. I’m committed to the urgent pursuit of progress so that we can help our clients bring life-changing treatments to patients faster and more efficiently,” said Leslie Orne. “Our industry is fast-paced, and Trinity has the passion and resources to drive new commercialization innovations that advance the entire healthcare ecosystem.”
